Asset Details
Do you wish to reserve the book?
Formoterol Attenuates Neutrophilic Airway Inflammation in Asthma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Formoterol Attenuates Neutrophilic Airway Inflammation in Asthma
Do you wish to request the book?
Formoterol Attenuates Neutrophilic Airway Inflammation in Asthma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Formoterol Attenuates Neutrophilic Airway Inflammation in Asthma
2005
Overview
Airway neutrophil levels are increased in patients with severe asthma and during asthma exacerbations. Long-acting β2-agonists (LABAs), such as formoterol, reduce the number of asthma exacerbations. While β2-agonists may affect neutrophil function in vitro, it is uncertain whether they have effects on neutrophilic inflammation in asthmatic patients in vivo.
In a double-blind randomized crossover study, we evaluated the effects of 4 weeks of treatment with formoterol (Turbuhaler), 24 μg bid, compared to placebo on sputum neutrophil numbers and interleukin (IL)-8 levels in asthmatic patients. Therapy with budesonide (administered via Turbuhaler), 400 μg bid for 4 weeks, was added at the end as a “gold standard” antiinflammatory effect comparison.
We studied 15 steroid-naïve nonsmoking patients who ranged from 19 to 51 years of age and had mild persistent asthma.
Formoterol therapy significantly reduced sputum IL-8 levels and neutrophil numbers compared to placebo. There was a significant correlation between the reduction in sputum IL-8 levels and the number of neutrophils, indicating that formoterol may attenuate neutrophilic airway inflammation by inhibiting IL-8 production.
Our data suggest that the LABA formoterol reduces neutrophilic airway inflammation in patients with mild asthma and that this might be beneficial in preventing asthma exacerbations.
Publisher
Elsevier Inc,American College of Chest Physicians
